Relmada Therapeutics, Inc. RLMD Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s share-based payment award options outstanding - number?
- Relmada Therapeutics, Inc. (RLMD) reported share-based payment award options outstanding - number of 15M in Q1 2026.
- What is the long-term trend for Relmada Therapeutics, Inc.'s share-based payment award options outstanding - number?
- Over 4 years (2020 to 2025), Relmada Therapeutics, Inc.'s share-based payment award options outstanding - number has grown at a 54.0% compound annual growth rate (CAGR), from 2.7M to 15M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.